Health Technology · Pharmaceuticals: Major · NSE: VENUSREM · data 2026-10-09
Venus Remedies Limited
Health check: Strong (8.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,610.1
Market cap
₹2,240 cr
P/E
18.5
P/B
—
ROE
16.8%
ROCE
14.5%
Debt / equity
0.02
Dividend yield
0.60%
1-year return
253.3%
52-week high
₹2,044.3
52-week low
₹432.1
Operating margin
17.2%
Growth
| Revenue (last 12 months) | ₹811 cr |
| Net profit (last 12 months) | ₹116 cr |
| Sales growth, 3 years (yearly) | 10.1% |
| Profit growth, 3 years (yearly) | 57.0% |
Similar companies
Dishman Carbogen Amcis Ltd. (DCAL) · Syncom Formulation (India) Ltd. (SYNCOMF) · Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VENUSREM in NSE Scanner →